Dr John M

cardiac electrophysiologist, cyclist, learner

  • Home
  • About
    • About Me
    • About the Blog
      • General Cardiology and Internal Medicine
    • Six Reasons why I Blog
    • What’s Electrophysiology?
    • ICD/Pacemaker
    • Electrophysiology Column / Medscape
    • Contact
  • Afib
    • AFib
    • AF in Athletes
    • The best tool to treat AF
    • Know your CHADS-VASC Score
    • 3 non-warfarin anticoagulants
    • AF ablation
      • 13 things to know about AF
      • Atrial Fib Ablation -2012 Update
      • Gender-Spec results of AF ablation
    • Female gender and stroke risk in AF
    • My AF Story
  • Heart Healthy
    • Heart Disease (by DrJohnM)
    • Healthy Living
    • Exercise
    • Nutrition
    • inflammation
  • Policy
    • Policy
    • Health Care
    • Health Care Reform
  • Doctoring
    • Doctoring
    • Knowledge
    • Reflection
    • General Medicine
      • Does your cholesterol level matter?
    • General Cardiolgy – Medicine
      • What is a normal heart rate?
      • Cardiology/Internal Med
      • General Cardiology
      • Athletic heart
        • The ECG of an athlete
      • General Medicine
      • Stroke
      • Statins
  • Cycling
    • DrJohnM on Cycling
    • How I became a bike racer
    • My top 12 Likes on Cycling
    • Cyclocross
      • A CX-Primer
    • Fitness
    • Athletic heart
    • The Mysterious Athletic Heart

Can Dabigatran (Pradaxa) be used before and after cardioversion?

January 4, 2011 By Dr John

Yesterday marked the two-month anniversary of the availability of the novel blood-thinner dabigatran (Pradaxa). It was approved for the use of preventing stroke in patients with non-valvular AF, but it has quickly taken on the inaccurate moniker of “the warfarin-substitute.”

Here’s the thinking: If stroke prevention in AF is accomplished by thinning the blood, and dabigatran is a blood thinner proven superior to warfarin, then it follows that it could be used for any warfarin indication. Things like clot prevention for mechanical heart valves, clots in the deep veins of the leg or lung, and inherited clotting disorders of the blood (ie…Factor V Leiden.), just to name four of the many other uses of warfarin.

We will see about the efficacy of dabigatran in these “other (warfarin) uses” in the future.  But for now, there are simpler and more clinically relevant questions that need answers.

One is: Can dabigatran replace warfarin before and after cardioversion?

Many patients with AF require the procedure, cardioversion—shocking the heart back to regular rhythm. To date, thinning the blood with warfarin before and after the shock is mandated.  And, unlike dabigatran, the level of blood-thinning with warfarin can be easily quantified—by measuring the INR level. (An INR of greater than 2.0 is an adequate blood-thinning effect.)

In the largest cardioversion study to date and the first to evaluate dabigatran in the setting of cardioversion, the RE-LY investigators found that when they looked back at the 1270 patients who underwent cardioversion in the 18,000 patient-strong RE-LY trial, “the frequencies of stroke and major bleeding within 30 days of cardioversion on the 2 doses of dabigatran were low and comparable to those on warfarin.”  Additionally they showed that the incidence of clots in the left atrial appendage (as defined by transesophageal echo or TEE ) were also low.

And they concluded: “dabigatran is a reasonable alternative to warfarin in patients requiring cardioversion.”

That’s good, because their findings make sense: if dabigatran was superior to warfarin in preventing strokes in AF, it ought to be effective in preventing strokes before and after shocking the heart out of AF.

The next question that AF doctors will have is whether dabigatran can be safely used before and after AF ablation?

My prediction is that the answer is yes.

Stay tuned.

JMM

  • Email
  • LinkedIn
  • Facebook
  • Twitter
  • More
  • Reddit

Related posts:

  1. A letter to the CEO of Boerhinger Ingelheim–on Pradaxa
  2. A coumadin substitute, we are almost there…
  3. Dabigatran excitement is building…
  4. Dabigatran: Finally a substitute for the dreaded coumadin is close…

Filed Under: AF ablation, Atrial fibrillation, Dabigatran/Rivaroxaban/Apixaban

John Mandrola, MD

Welcome, Enjoy, Interact. john-mandrola I am a cardiac electrophysiologist practicing in Louisville KY. I am also a husband to a palliative care doctor, a father, a bike racer, and a regular columnist at theHeart.org | Medscape

My First Book is Now Available…

Email Newsletter

Search the Site

Categories

Find me on theheart.org | Medscape Cardiology

  • Electrophysiology commentary on Medscape/Cardiology

Mandrola on Medscape

  • My Medscape column on general medical matters

For patients...Educational posts

  • 13 things to know about Atrial Fibrillation — 2014
  • A new cure of AF
  • Adding a new verb to doctoring: To deprescribe is to do a lot
  • AF ablation — 2015 A Cautionary Note
  • AF Ablation in 2012–An easier journey?
  • Atrial Flutter — 15 facts you may want to know.
  • Benign PVCs: A heart rhythm doctor’s approach.
  • Caution with early Cardioversion
  • Decisions of 2 low-risk cases of PAF
  • Defining success in AF ablation in 2014
  • Four commonly asked questions on AF ablation
  • Inflammation and AF — Get off the gas
  • Ten things to expect after AF ablation
  • The medical decsion as a gamble
  • The most important verb in our health crisis
  • Wellness Requires Ownership

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.